全文获取类型
收费全文 | 105篇 |
免费 | 18篇 |
专业分类
耳鼻咽喉 | 1篇 |
基础医学 | 9篇 |
临床医学 | 3篇 |
内科学 | 65篇 |
皮肤病学 | 2篇 |
神经病学 | 5篇 |
特种医学 | 4篇 |
外科学 | 3篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 2篇 |
肿瘤学 | 26篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 7篇 |
2014年 | 1篇 |
2013年 | 1篇 |
2012年 | 3篇 |
2011年 | 3篇 |
2010年 | 4篇 |
2009年 | 2篇 |
2008年 | 2篇 |
2006年 | 7篇 |
2005年 | 6篇 |
2004年 | 6篇 |
2003年 | 9篇 |
2002年 | 4篇 |
2001年 | 4篇 |
2000年 | 8篇 |
1999年 | 7篇 |
1998年 | 4篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1991年 | 1篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1987年 | 2篇 |
1985年 | 1篇 |
1982年 | 2篇 |
1966年 | 1篇 |
排序方式: 共有123条查询结果,搜索用时 19 毫秒
1.
Molina TJ Delmer A Cymbalista F Le Tourneau A Perrot JY Ramond S Marie JP Audouin J Zittoun R Diebold J 《Virchows Archiv : an international journal of pathology》2000,437(6):591-598
Mantle cell lymphoma (MCL) is a well-defined peripheral B-cell lymphoma usually diagnosed upon peripheral lymph node biopsy. We report eight cases of peripheral B-cell leukaemia that demonstrate presumptive evidence of mantle cell characteristics. The patients had a median age of 68.5 years, and five were male. All presented with an enlarged spleen without any peripheral lymphadenopathies, and they were leukaemic at presentation (median lymphocytosis, 38x10(9)/l). Morphological diagnosis of MCL was very difficult in five cases but easier in three because we were able to analyse either pre- or post-mortem lymph nodes and spleen. The immunophenotype of blood lymphocytosis using flow cytometry, the presence of a t(11;14)(q13;q32) and a cyclin D1 expression by leukaemic cells all fit with the diagnosis of MCL. All patients progressed and died with a median overall survival of 8 months. Multifocal areas of transformation in blastoid or large cell variants were observed in the three autopsied patients. In summary, one should consider the diagnosis of MCL at presentation in leukaemic phase even in the absence of peripheral adenopathies. 相似文献
2.
AIMS: Diffuse haemangiomatosis of the spleen is a rare benign vascular condition occurring as a manifestation of systemic angiomatosis or, less commonly, confined to the spleen. It is sometimes accompanied by severe disturbance of blood coagulation. The goal of this study was to characterize an additional case of isolated diffuse haemangiomatosis of the spleen and to determine the histogenesis of this lesion which remains obscure. METHODS AND RESULTS: We describe a case of isolated diffuse haemangiomatosis of the spleen in which histological and immunohistological findings suggested the possibility of a malformative tumour-like lesion. The pathological cavernous vessels were distributed randomly through the red pulp, without continuity with sinuses. The endothelial cells expressed vimentin, factor VIII related antigen and CD34, but not CD8. Some cells lining the sinus lumen expressed CD68, lysozyme and myeloperoxidase. In addition, trabecular veins presented with intimal thickening. These results allow making a diagnosis between diffuse haemangiomatosis and other tumours/tumour-like lesions of the spleen, especially littoral cell angioma, splenoma and peliosis. CONCLUSION: If diffuse haemangiomatosis is usually classified as a benign proliferation of endothelial cells, we suggest that diffuse haemangiomatosis, when confined to the spleen, could be a tumour-like vascular lesion. In this hypothesis, the aetiology may be hamartomatous or malformative as is suspected in arterio-venous haemangioma of the lower extremities. The histogenesis is still questionable and no definitive proof in favour of one or the other hypothesis has been reported. 相似文献
3.
SPONTANEOUS REMISSION IN ACUTE MYELOID LEUKAEMIA 总被引:1,自引:0,他引:1
Alain Delmer Emmanuel Heron Jean-Pierre Marie Robert Zittoun 《British journal of haematology》1994,87(4):880-882
4.
We report a case of visceral larva migrans in an adult with fever, night sweats, weight loss, hilar and mediastinal lymphadenopathy, bilateral pleural effusion, and eosinophilia-mimicking lymphoma. Visceral larva migrans was diagnosed subsequently because of negative findings for malignancy and positive serologic test result for Toxocara canis. Progressive improvement was observed with albendazole therapy. 相似文献
5.
Delfau-Larue MH de Leval L Joly B Plonquet A Challine D Parrens M Delmer A Salles G Morschhauser F Delarue R Brice P Bouabdallah R Casasnovas O Tilly H Gaulard P Haioun C 《Haematologica》2012,97(10):1594-1602
Background In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often infected by Epstein-Barr virus, are found in tumor tissues. We postulated that the disruption of putative B-T interactions and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rituximab) could improve the clinical outcome produced by conventional chemotherapy. DESIGN AND METHODS: Twenty-five newly diagnosed patients were treated, in a phase II study, with eight cycles of rituximab + chemotherapy (R-CHOP21). Tumor infiltration, B-blasts and Epstein-Barr virus status in tumor tissue and peripheral blood were fully characterized at diagnosis and were correlated with clinical outcome. RESULTS: A complete response rate of 44% (95% CI, 24% to 65%) was observed. With a median follow-up of 24 months, the 2-year progression-free survival rate was 42% (95% CI, 22% to 61%) and overall survival rate was 62% (95% CI, 40% to 78%). The presence of Epstein-Barr virus DNA in peripheral blood mononuclear cells (14/21 patients) correlated with Epstein-Barr virus score in lymph nodes (P<0.004) and the detection of circulating tumor cells (P=0.0019). Despite peripheral Epstein-Barr virus clearance after treatment, the viral load at diagnosis (>100 copy/μg DNA) was associated with shorter progression-free survival (P=0.06). Conclusions We report here the results of the first clinical trial targeting both the neoplastic T cells and the microenvironment-associated CD20(+) B lymphocytes in angioimmunoblastic T-cell lymphoma, showing no clear benefit of adding rituximab to conventional chemotherapy. A strong relationship, not previously described, between circulating Epstein-Barr virus and circulating tumor cells is highlighted. 相似文献
6.
7.
Karim Maloum Catherine Settegrana Elise Chapiro Bruno Cazin Stéphane Leprêtre Alain Delmer Michel Leporrier Brigitte Dreyfus Olivier Tournilhac Beatrice Mahe Florence Nguyen-Khac Claude Lesty Frederic Davi Hélène Merle-Béral 《Annals of hematology》2009,88(12):1215-1221
Several prognostic factors can predict the rapid progression in chronic lymphocytic leukaemia (CLL), including IGHV mutational status, cytogenetic abnormalities and, more recently, LPL/ADAM29 expression. In contrast, few studies have been devoted to the influence of these factors on clinical outcome in responding patients after therapy. We here propose to analyse the impact of IGHV gene status, LPL and ADAM29 gene expression on disease-free survival (DFS) and overall survival (OS) in 41 stage B or C CLL patients in remission after oral fludarabine plus cyclophosphamide. The median follow-up was of 64 (16–74) months. Sequencing of IGHV showed mutated (M) VH genes in 16 of 41 cases and unmutated (UM) in 25 cases. Analysis of LPL and ADAM29 expression in 35 of 41 cases showed overexpression of ADAM29 in 17 cases (14 M and three UM) and LPL in 18 cases (all UM). Patients expressing UM IGHV and LPL had shorter DFS and OS when compared to patients expressing M IGHV and/or ADAM29. Furthermore, blood minimal residual disease (MRD) evaluation using four-colour flow cytometry was performed in 33 out the 41 patients. We showed that patients who achieved phenotypic remission displayed longer DFS than those with MRD+. Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies. 相似文献
8.
F Lefrère A Delmer F Suzan V Levy C Belanger M Djabarri B Arnulf G Damaj N Maillard V Ribrag M Janvier C Sebban R-O Casasnovas R Bouabdallah F Dreyfus V Verkarre E Delabesse F Valensi E McIntyre N Brousse B Varet O Hermine 《Leukemia》2002,16(4):587-593
Mantle cell lymphoma (MCL) is a distinct clinico-pathological entity with a poor prognosis. We have conducted a prospective study in patients with MCL to evaluate a therapeutic strategy in which CHOP polychemotherapy was followed by DHAP if CHOP failed to induce complete remission. Responding patients then proceeded to an intensification therapy with autologous peripheral blood stem cell transplantation (APBSCT). Twenty-eight consecutive patients with newly diagnosed aggressive MCL were included. After four cycles of CHOP regimen, two complete responses (CR) were obtained (7%) and 14 (50%), five (18%) and seven (25%) patients achieved partial (PR), minor (MR) and no response, respectively (one patient died from septic complications during CHOP induction). The two patients in CR after CHOP underwent intensification with TBI, high-dose cyclophosphamide-etoposide and APBSCT. The other twenty-five patients received DHAP and in this group a response rate of 92% (21 CR (84%), two PR (8%)) was observed. Two patients had progressive disease. The twenty-three responding patients received high-dose therapy (TAM8 regimen: TBI-cytarabine-melphalan) followed by APBSCT. One of the two partial responding patients achieved CR after TAM8. After a median follow-up of 47.6 months (range, 14-70), seven patients have relapsed. Our data confirm that: (1) CHOP regimen induces a low CR rate in MCL; (2) CHOP plus DHAP appears to be much more efficient and allows a large proportion of patients to proceed to high-dose therapy in CR; (3) consolidation therapy including TBI and high-dose Arac-C followed by APBSCT may improve event-free survival. 相似文献
9.
Gerhard W. Brauer Paul D. Fisher Delmer B. Pengelly Gordon W. Ritchie 《Journal of digital imaging》1990,3(2):95-100
Chest radiography provides one of the great challenges to digital diagnostic imaging because of (1) the relatively large size of the chest field, (2) the contrast range required to resolve subtle pathological changes in soft tissue density, and (3) the high degree of spatial resolution required to discriminate pathological detail. The field size problem was resolved by using a 57-cm image intensifier whose video output of the chest could be digitized. The issue of contrast resolution was addressed in a recently completed receiver-operating characteristic study of the detectability of low-contrast densities in a humanoid chest phantom. The latter indicated that, despite the smaller size of the digital image, they were adequate for resolving clinically significant soft-tissue densities. The question of spatial resolution in digital diagnostic images is addressed in the study presented. A set of 41 clinical cases were selected to provide the typical range of diagnostic type experienced in routine diagnostic radiology. The images were each presented as conventional film, digital laser-printer, and digital video images. The results of an ROC analysis of five readers' performance in each of the viewing modes is presented. 相似文献
10.
Salvage outcomes in patients with first relapse after fludarabine,cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience
下载免费PDF全文
![点击此处可从《American journal of hematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Luc‐Matthieu Fornecker Thérèse Aurran‐Schleinitz Anne‐Sophie Michallet Bruno Cazin Romain Guieze Marie‐Sarah Dilhuydy Jean‐Marc Zini Cécile Tomowiak Stéphane Lepretre Florence Cymbalista Annie Brion Pierre Feugier Alain Delmer Véronique Leblond Loïc Ysebaert 《American journal of hematology》2015,90(6):511-514
The optimal management of patients with relapsed chronic lymphocytic leukemia (CLL) is dictated by the type of prior therapy, duration of prior response, presence of genomic aberrations, age, and comorbidities. The patterns of relapses and the clinical outcomes of second‐line options after fludarabine‐cyclophosphamide‐rituximab (FCR) is given as a frontline treatment are currently unknown. In this retrospective and non‐randomized study, we report the outcomes of 132 patients from databases of 14 French CLL study group centers who needed a second‐line treatment after FCR frontline. Bendamustine + rituximab (BR) was the most frequently used second‐line regimen, followed by alemtuzumab‐based regimens, R‐CHOP, and FCR. Median progression‐free survival (PFS) was 18 months after BR with a median overall survival (OS) not reached. We also found that response durations of < 36 months and the presence of del(17p) are critical factors that contribute to poor overall survival. BR appears to be an effective salvage regimen in our series, both in terms of progression‐free and overall survival. Patients who relapsed less than 36 months after FCR have a poor outcome, not significantly different in this study from patients with early relapses less than 12 or 24 months. Am. J. Hematol. 90:511–514, 2015. © 2015 Wiley Periodicals, Inc. 相似文献